Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.58 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6579519 | 0.90 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6579637 | 0.89 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6581555 | 0.85 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6581503 | 0.85 | PTGS1 (0.60) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6579341 | 0.85 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6581283 | 0.84 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6581589 | 0.83 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6581827 | 0.83 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL4471588 | 0.80 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL6579200 | 0.79 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1112265-B1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2004-01-14 | — | — | EP | claimed |
| US-6432988-B1 | RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT | MERCKLE GMBH (DE) | 2002-08-13 | — | — | US | claimed |
| EP-1112265-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2001-07-04 | — | — | EP | claimed |
| WO-2000017192-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2000-03-30 | — | — | WO | claimed |
| EP-1112265-B1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-6432988-B1 | RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT | MERCKLE GMBH (DE) | 2002-08-13 | — | — | US | disclosed |
| EP-1112265-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000017192-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2000-03-30 | — | — | WO | disclosed |